Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2868 plus anlotinib and chemotherapy as first-line treatment for metastatic pancreatic cancer
ChiCTR2400081442Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Mar 2024
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TQB2868 in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival (PFS). Planned start Mar 2024; status: not yet recruiting.
02
Drugs
TQB2868
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400081442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081442.